The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
Abstract
Summary: Although there is no need for routine coagulation monitoring with rivaroxaban – an oral, direct factor Xa inhibitor – a haemostasis assay might be valuable to measure its pharmacodynamic effects. This study aimed to find assays, among those commercially available, to measure rivaroxaban pharmacodynamics. Several global conventional clotting tests, as well as clotting or chromogenic assays to measure anti-factor Xa activity, were studied. A thrombin generation test using calibrated automated thrombogram was also done. Tests were performed with the indirect factor Xa inhibitor fondaparinux for comparison. A concentration-dependent prolongation of prothrombin time (PT), dilute PT, and activated partial thromboplastin time was observed with rivaroxaban. The results varied depending on the reagents. This variability cannot be standardised with the international normalised ratio system commonly used for vitamin K antagonists. Using a standard calibration curve, PT test results can be expressed in plasma concentrations of rivaroxaban rather than PT seconds or ratio. Standard methods for HepTest and two-step prothrombinase-induced clotting time (PiCT) resulted in a paradoxical response, with low concentrations of rivaroxaban reducing clotting times. This was not observed with shorter incubation times, or when antithrombin-deficient (immunodepleted) plasma was used. The chromogenic tests found a dose-dependent relationship between anti-factor Xa activity and rivaroxaban concentration. Modified specific factor Xa chromogenic assays are being further investigated. One-step PiCT and HepTest with shortened incubation times, as well as the widely available PT assay (using a rivaroxaban calibrator) could be useful to monitor the pharmacodynamic effects of rivaroxaban accurately. Finally, all clotting and chromogenic assays showed a concentration-dependent effect induced by rivaroxaban.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Hirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M., & Weitz, J. I. (2008) · Chest · doi:10.1378/chest.08-0689 · Cited by 755
Self-citationHemker, H. C., Giesen, P., AlDieri, R., Regnault, V., de Smed, E., Wagenvoord, R., Lecompte, T., & Béguin, S. (2002) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000073575 · Cited by 679
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
PERZBORN, E., STRASSBURGER, J., WILMEN, A., POHLMANN, J., ROEHRIG, S., SCHLEMMER, K.-H., & STRAUB, A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01166.x · Cited by 590
Self-citationCOFACTOR PROTEINS IN THE ASSEMBLY AND EXPRESSION OF BLOOD CLOTTING ENZYME COMPLEXES
Mann, K. G., Jenny, R. J., & Krishnaswamy, S. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.004411 · Cited by 536
The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants
Thiagarajan, P., Pengo, V, & Shapiro, S. (1986) · Blood · doi:10.1182/blood.v68.4.869.869 · Cited by 422
TURPIE, A. G. G., FISHER, W. D., BAUER, K. A., KWONG, L. M., IRWIN, M. W., KÄLEBO, P., MISSELWITZ, F., & GENT, M. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01602.x · Cited by 302
ERIKSSON, B. I., BORRIS, L., DAHL, O. E., HAAS, S., HUISMAN, M. V., KAKKAR, A. K., MISSELWITZ, F., & KÄLEBO, P. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01657.x · Cited by 302
The Thrombogram: Monitoring Thrombin Generation in Platelet Rich Plasma
Giesen, P., Ramjee, M., Wagenvoord, R., Béguin, S., & Hemker, C. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613868 · Cited by 287
Cited by
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology
Kozek-Langenecker, S. A., Afshari, A., Albaladejo, P., Santullano, C. A. A., De Robertis, E., Filipescu, D. C., Fries, D., Görlinger, K., Haas, T., Imberger, G., et al. (2013) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835f4d5b · Cited by 909
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Mueck, W., Stampfuss, J., Kubitza, D., & Becka, M. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0100-7 · Cited by 612
Marlu, R., Hodaj, E., Paris, A., Albaladejo, P., Crackowski, J., & Pernod, G. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-03-0179 · Cited by 501
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
Cuker, A., Siegal, D. M., Crowther, M. A., & Garcia, D. A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.065 · Cited by 449
Metadata
- Authors
- Martinoli, J.-L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F., Perzborn, E., & Samama, M. M.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2010
- Volume
- 103
- Issue
- 04
- Pages
- 815-825
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2157224841
- Cited by
- 449
- References
- 14
- FWCI
- 34.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor. https://app.cochat.ai/papers/10.1160/th09-03-0176
- The paper
- Martinoli, J.-L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F., Perzborn, E., & Samama, M. M. (2010). Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor. Thrombosis and Haemostasis. https://doi.org/10.1160/th09-03-0176
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.